Pliant Therapeutics, INC 10-Q quarterly reports

Pliant Therapeutics filed its Form 10-Q for the quarter ended June 30, 2026, detailing continued net losses and operational adjustments, while advancing its PLN-101095 oncology program.

Pliant Therapeutics reported a net loss of $20.0 million for the first quarter of 2026, a significant decrease from the prior year's loss of $56.2 million, driven by reduced R&D expenses.

Pliant Therapeutics reported significant net losses and a 45% workforce reduction following the discontinuation of its lead IPF drug, bexotegrast, while advancing its oncology and muscular dystrophy programs.

Pliant Therapeutics discontinues development of bexotegrast in Idiopathic Pulmonary Fibrosis (IPF) due to an unfavorable risk-benefit profile, leading to a workforce reduction and strategic reprioritization of its pipeline.

Pliant Therapeutics reports Q1 2025 results, including the discontinuation of the BEACON-IPF trial and a strategic realignment involving a significant workforce reduction.

Pliant Therapeutics' third quarter 2024 report highlights ongoing clinical trial progress and financial updates, with a focus on their lead drug candidate, bexotegrast.

Pliant Therapeutics reports a net loss of $55.9 million for the second quarter of 2024, while highlighting progress in clinical trials and pipeline development.

Pliant Therapeutics reports progress in clinical trials and secures additional funding in its first quarter 2024 financial results.